Core Insights - Climb Bio, Inc. has appointed Dr. Perrin Wilson as Chief Business Officer, bringing over 17 years of experience in the pharmaceutical and biotech industry [1][2] - Dr. Wilson will lead pre-commercial planning, communications, and business development efforts, focusing on advancing treatments for immune-mediated diseases [2] - The company is currently developing two key assets: budoprutug, an anti-CD19 monoclonal antibody, and CLYM116, an anti-APRIL monoclonal antibody for IgA nephropathy [3] Company Overview - Climb Bio, Inc. is a clinical-stage biotechnology company focused on therapeutics for patients with immune-mediated diseases [3] - The pipeline includes budoprutug, which has shown B-cell depletion potential, and CLYM116, which is in IND-enabling studies [3] Leadership Background - Dr. Wilson previously served as Senior Vice President at Nuvalent and held various roles at Forma Therapeutics/Novo Nordisk, including leading a $1.1 billion acquisition [2] - She has extensive experience in business development and strategy, including a $5.2 billion acquisition at Takeda [2]

Company Overview - Climb Bio, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases [2] - The company's pipeline includes budoprutug, an anti-CD19 monoclonal antibody, and CLYM116, an anti-APRIL monoclonal antibody [2] Upcoming Event - Members of Climb Bio's executive team will participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11-12, 2025 [1] - The presentation is scheduled for February 12, 2025, at 9:20 a.m. ET [2]

Transaction Expands Climb Bio’s Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases New Program is a Highly Potent, Fc-engineered anti-APRIL Monoclonal Antibody Specifically Designed to Address Patient Needs Preclinical Data Expected to be Shared Later in 2025 WELLESLEY HILLS, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced it has entered into an exclusive license agreement with Beijing Mabworks Biotech Co., Ltd. (NEEQ Code: 874070, Mabworks) ...

Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENTS OF OPERATIONS On June 27, 2024 (the "Closing Date"), Climb Bio, Inc. (the "Company" or "Climb"), formerly known as Eliem Therapeutics, Inc., completed its acquisition of Tenet Medicines, Inc., a Delaware corporation ("Tenet"), pursuant to the terms of the Agreement and Plan of Merger and Reorganization, dated as of April 10, 2024 (the "Acquisition Agreement"), by and among the Company, Tango Merger Sub, Inc., a Delaware corporation and a wholly ...

Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors FDA Clearance of Investigational New Drug Application (IND) for systemic lupus erythematosus (SLE) Expanded Management Team with the Appointment of Gary Hao, Ph.D. as Vice President of Chemistry, Manufacturing and Controls Highlights Timing of Key Upcoming Milestones Cash Runway Remains through 2027 Expected to Enable Delivery of Key Value Inflection Points WELLESLEY HILLS, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40708 CLIMB BIO, INC. (Exact Name of Registra ...

WELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio’s Chair of its Board of Directors. Dr. Williams will assume the role of Chair of the Board, succeeding Andrew Levin, who will remain on the Board as a director, while Liam Ratcliffe will step down from his position as a director. Dr. Williams has over 30 years of executive leadership experience in the biotechnology sector. Throughout his career, Dr. W ...